Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Respiratory Syncytial Virus Infection

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    107 result(s) found for: Respiratory Syncytial Virus Infection. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2022-001981-36 Sponsor Protocol Number: 219238 Start Date*: 2022-11-15
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase 3, observer-blind, randomized, placebo controlled study to evaluate the non inferiority of the immune response and safety of the RSVPreF3 OA investigational vaccine in adults 50-59 years of...
    Medical condition: Respiratory syncytial virus infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035732 Pneumonia respiratory syncytial viral PT
    21.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    21.1 10021881 - Infections and infestations 10069811 Respiratory syncytial virus bronchitis PT
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    21.1 10021881 - Infections and infestations 10035692 Pneumonia due to respiratory syncytial virus LLT
    21.1 10021881 - Infections and infestations 10067384 Respiratory syncytial virus pneumonitis LLT
    21.1 10021881 - Infections and infestations 10052200 Respiratory syncytial virus infection NOS LLT
    21.1 10021881 - Infections and infestations 10066741 Respiratory syncytial virus infection recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Ongoing) NL (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004680-51 Sponsor Protocol Number: 212496 Start Date*: 2021-01-18
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A phase 3, randomized, open-label, multi-country study to evaluate the immunogenicity, safety, reactogenicity and persistence of a single dose of the RSVPreF3 OA investigational vaccine and differe...
    Medical condition: Healthy volunteers (Active immunization for the prevention of disease caused by RSV in adults aged 60 years or above)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035732 Pneumonia respiratory syncytial viral PT
    21.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    21.1 10021881 - Infections and infestations 10069811 Respiratory syncytial virus bronchitis PT
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    21.1 10021881 - Infections and infestations 10035692 Pneumonia due to respiratory syncytial virus LLT
    21.1 10021881 - Infections and infestations 10067384 Respiratory syncytial virus pneumonitis LLT
    21.1 10021881 - Infections and infestations 10052200 Respiratory syncytial virus infection NOS LLT
    21.1 10021881 - Infections and infestations 10066741 Respiratory syncytial virus infection recurrent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000825-33 Sponsor Protocol Number: MI-CP117 Start Date*: 2012-03-09
    Sponsor Name:MedImmune LLC
    Full Title: A Phase 3 Study of MEDI-524 (Motavizumab) for the Prevention of RSV Disease Among Native American Infants in the Southwestern United States
    Medical condition: Serious Lower Respiratory Tract disease caused by RSV
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-000039-27 Sponsor Protocol Number: MI-CP110 Start Date*: 2004-08-09
    Sponsor Name:MedImmune, Inc.
    Full Title: A pivotal phase 3 study of MEDI-524 (Numax), an enhanced potency humanized respiratory syncytial virus (RSV) monoclonal antibody, for the prophylaxis of serious RSV disease in high-risk children.
    Medical condition: Serious respiratory syncytial virus (RSV) disease
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061603
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) CZ (Completed) DK (Completed) IS (Completed) AT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005742-58 Sponsor Protocol Number: 204813 Start Date*: 2016-03-31
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomised, observer-blind, controlled, study to assess the reactogenicity and safety of a single intramuscular dose of GlaxoSmithKline (GSK) Biologicals’ investigational respiratory sy...
    Medical condition: Healthy volunteers (prevention of severe RSV disease in infants by transfer of maternal antibodies following active single dose immunisation of pregnant women).
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    18.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    18.1 10021881 - Infections and infestations 10035692 Pneumonia due to respiratory syncytial virus LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000753-28 Sponsor Protocol Number: 212494 Start Date*: 2021-05-05
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose and annual revaccination of GSK’s RSVPreF3 OA investigational vaccine in ...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035732 Pneumonia respiratory syncytial viral PT
    21.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    21.1 10021881 - Infections and infestations 10069811 Respiratory syncytial virus bronchitis PT
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    21.1 10021881 - Infections and infestations 10035692 Pneumonia due to respiratory syncytial virus LLT
    21.1 10021881 - Infections and infestations 10067384 Respiratory syncytial virus pneumonitis LLT
    21.1 10021881 - Infections and infestations 10052200 Respiratory syncytial virus infection NOS LLT
    21.1 10021881 - Infections and infestations 10066741 Respiratory syncytial virus infection recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing) DE (Ongoing) IT (Ongoing) SE (Prematurely Ended) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002688-14 Sponsor Protocol Number: 201510 Start Date*: 2015-02-11
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase II, randomised, observer-blind, controlled, multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of different formulations of GlaxoSmit...
    Medical condition: Healthy, non-pregnant women (intended indication: prevention of severe RSV disease in infants by transfer of maternal antibodies following active single dose immunisation of pregnant women)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    17.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    17.1 10021881 - Infections and infestations 10035692 Pneumonia due to respiratory syncytial virus LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001340-62 Sponsor Protocol Number: 208068 Start Date*: 2019-01-08
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ investigational unadjuvanted RSV maternal vaccine compared to placebo when administered to healthy non-pregnant...
    Medical condition: Healthy volunteers (Prevention of RSV LRTI in infants)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10035692 Pneumonia due to respiratory syncytial virus LLT
    20.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    20.1 10021881 - Infections and infestations 10066741 Respiratory syncytial virus infection recurrent LLT
    20.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    20.1 10021881 - Infections and infestations 10052200 Respiratory syncytial virus infection NOS LLT
    20.1 10021881 - Infections and infestations 10067384 Respiratory syncytial virus pneumonitis LLT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005980-30 Sponsor Protocol Number: 53718678RSV2008 Start Date*: 2021-11-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir (JNJ-53718678) in Adult Outpatients with Respiratory Syncytial Virus (RSV) Infection...
    Medical condition: Respiratory Syncytial Virus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) PL (Completed) HU (Ongoing) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-001671-35 Sponsor Protocol Number: MI-CP124 Start Date*: 2005-08-16
    Sponsor Name:MedImmune, Inc.
    Full Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Childr...
    Medical condition: Serious respiratory syncytial virus (RSV) disease in children with hemodynamically significant congential heart disease (CHD).
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061603 PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) SE (Completed) CZ (Prematurely Ended) BE (Completed) DE (Completed) DK (Completed) AT (Prematurely Ended) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001651-49 Sponsor Protocol Number: ALX0171-C201 Start Date*: 2016-11-07
    Sponsor Name:Ablynx NV
    Full Title: A randomized, double-blind, placebo-controlled, multicenter dose ranging study of ALX-0171 in infants and young children hospitalized for respiratory syncytial virus lower respiratory tract infection
    Medical condition: RSV lower respiratory tract infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) LV (Completed) HU (Completed) ES (Completed) EE (Completed) LT (Completed) SK (Completed) BE (Completed) BG (Completed) CZ (Completed) Outside EU/EEA PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000849-38 Sponsor Protocol Number: 208851 Start Date*: 2018-12-14
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase I/II, randomized, placebo-controlled, observer-blind, multicenter study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ investigational respiratory syncytial v...
    Medical condition: Volunteers (Active immunisation for the prevention of disease caused by respiratory syncytial virus (RSV) in adults aged 60 years or above)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    20.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    20.1 10021881 - Infections and infestations 10035692 Pneumonia due to respiratory syncytial virus LLT
    20.1 10021881 - Infections and infestations 10052200 Respiratory syncytial virus infection NOS LLT
    20.1 10021881 - Infections and infestations 10066741 Respiratory syncytial virus infection recurrent LLT
    20.1 10021881 - Infections and infestations 10067384 Respiratory syncytial virus pneumonitis LLT
    20.1 10021881 - Infections and infestations 10069811 Respiratory syncytial virus bronchitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004527-42 Sponsor Protocol Number: W10-664 Start Date*: 2015-02-03
    Sponsor Name:Abbott Laboratories LLC
    Full Title: A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis® in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation.
    Medical condition: Severe Respiratory Syncytial Virus Infection (RSV)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-005192-16 Sponsor Protocol Number: 100/2004/O/Sper Start Date*: 2005-01-18
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: THE EFFICACY OF DEXAMETHASONE IN MECHANICALLY VENTILATED CHILDREN WITH LOWER RESPIRATORY TRACT INFECTION CAUSED BY RESPIRATORY SYNCYTIAL VIRUS
    Medical condition: bronchiolitis and pneumonia correlated Rsv-LRTI
    Disease: Version SOC Term Classification Code Term Level
    6.1 10035732 PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002475-29 Sponsor Protocol Number: GS-US-218-1502 Start Date*: 2015-02-10
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT...
    Medical condition: Respiratory Syncytial Virus (RSV) Infection of the lower respiratory tract.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10039247 RSV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002095-26 Sponsor Protocol Number: 64041575RSV2002 Start Date*: 2018-06-11
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children with a History of Respiratory...
    Medical condition: Respiratory syncytial virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FR (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) PT (Completed) FI (Completed) SK (Prematurely Ended) IE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004003-41 Sponsor Protocol Number: 217354 Start Date*: 2022-02-11
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A Phase III, randomized, open-label, active vaccine-controlled crossover study to evaluate the reactogenicity, safety and immune response of unadjuvanted RSV maternal vaccine in healthy non-pregnan...
    Medical condition: Healthy volunteers (prevention of RSV-associated lower respiratory tract illnesses (LRTIs))
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035732 Pneumonia respiratory syncytial viral PT
    21.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    21.1 10021881 - Infections and infestations 10066741 Respiratory syncytial virus infection recurrent LLT
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    21.1 10021881 - Infections and infestations 10052200 Respiratory syncytial virus infection NOS LLT
    21.1 10021881 - Infections and infestations 10067384 Respiratory syncytial virus pneumonitis LLT
    21.1 10021881 - Infections and infestations 10069811 Respiratory syncytial virus bronchitis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017487-16 Sponsor Protocol Number: ALN-RSV01-109 Start Date*: 2010-02-25
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infec...
    Medical condition: Lung transplant patients with respiratory syncytial virus (RSV) infection
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10052200 Respiratory syncytial virus infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003356-23 Sponsor Protocol Number: ALX0171-C204 Start Date*: 2018-06-08
    Sponsor Name:Ablynx NV
    Full Title: A randomized, double-blind, multicenter study to evaluate the efficacy and safety of ALX-0171 versus placebo, in addition to standard of care, in adults who have undergone hematopoietic stem cell t...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002137-58 Sponsor Protocol Number: GS-US-218-1227 Start Date*: 2014-09-29
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respirato...
    Medical condition: Respiratory Syncytial Virus (RSV) Infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10039247 RSV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 26 23:46:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA